Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: BoredMember who wrote (10114)	4/20/2018 1:38:50 PM
From: old 'n cranky	1 Recommendation Recommended By mattstat Read Replies (1) \| Respond to of 12873

"has Nanoviricides ever "screwed up clinical testing and submission strategy and paperwork"?" Nope. Hasn't had the chance to.

To: BoredMember who wrote (10114)	4/20/2018 6:30:51 PM
From: HardToFind	Respond to of 12873

And for the record, has Nanoviricides ever "screwed up clinical testing and submission strategy and paperwork"? NNVC has a perfect record: zero for zero...unless you count never getting into position to file one after 13 years of opportunity. However, Saliva Diagnostic Systems didn't have the cleanest compliance record. See: casewatch.org And, it's remarkably easy for a small company to screw up it's clinical test strategy...it happens all the time. It is a red flag for indicating potentially marginal management. Example: TTPH has done it twice in less than a year. Last year: TRXC did a real number on a medical device 510 (k) submission.